Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs

C. Matrone; R. Pivonello; A. Colao; P. Cappabianca; L. M. Cavallo; M. L. Del Basso De Caro; J. E. Taylor; M. D. Culler; G. Lombardi; G. F. Di Renzo; L. Annunziato

doi:10.1159/000077272

Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs

C. Matrone, R. Pivonello, A. Colao, P. Cappabianca, L. M. Cavallo, M. L. Del Basso De Caro, J. E. Taylor, M. D. Culler, G. Lombardi, G. F. Di Renzo, L. Annunziato

IRCCS SDN

Research output: Contribution to journal › Article › peer-review

Abstract

The role of somatostatin (SS) receptor subtype 1 (SSTR₁) in mediating the inhibitory effect of SS on growth hormone (GH) secreting pituitary tumors has been recently demonstrated. In the present study, we evaluated the effect of the selective SSTR₁ agonist BIM-23745 on in vitro GH secretion in GH-secreting pituitary tumor cells, deriving from patients resistant or partially responsive to octreotide long-acting release (octreotide-LAR) or lanreotide therapy in vivo and expressing SSTR₁ mRNA. In addition, the inhibiting effect of BIM-23745 on the GH secretion was compared with that of octreotide. Our data demonstrate that (1) SSTR₁ receptor was present in 56.25% (9/16) of the GH-secreting adenomas examined; (2) in all GH-secreting pituitary tumors that expressed SSTR₁, BIM-23745 significantly inhibited GH secretion in vitro, and (3) when SSTR ₁ subtype was present in tumors from patients resistant to octreotide-LAR or lanreotide therapy, BIM-23745 was able to inhibit the in vitro GH secretion. In conclusion, the results of the current study suggest that SS analogs selective for the SSTR₁ may represent a further useful approach for the treatment of acromegaly in patients resistant or partially responsive to octreotide-LAR or lanreotide treatment in vivo.

Original language	English
Pages (from-to)	142-148
Number of pages	7
Journal	Neuroendocrinology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1159/000077272
Publication status	Published - 2004

Keywords

Acromegaly
Clinical neuroendocrinology
Growth hormone
Insulin-like growth factors
Somatostatin
Somatostatin analogs
Somatostatin receptors

ASJC Scopus subject areas

Endocrinology
Neuroscience(all)

Access to Document

10.1159/000077272

Fingerprint Dive into the research topics of 'Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs'. Together they form a unique fingerprint.

Cite this

Matrone, C., Pivonello, R., Colao, A., Cappabianca, P., Cavallo, L. M., Del Basso De Caro, M. L., Taylor, J. E., Culler, M. D., Lombardi, G., Di Renzo, G. F., & Annunziato, L. (2004). Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology, 79(3), 142-148. https://doi.org/10.1159/000077272

Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. / Matrone, C.; Pivonello, R.; Colao, A.; Cappabianca, P.; Cavallo, L. M.; Del Basso De Caro, M. L.; Taylor, J. E.; Culler, M. D.; Lombardi, G.; Di Renzo, G. F.; Annunziato, L.

In: Neuroendocrinology, Vol. 79, No. 3, 2004, p. 142-148.

Research output: Contribution to journal › Article › peer-review

Matrone, C, Pivonello, R, Colao, A, Cappabianca, P, Cavallo, LM, Del Basso De Caro, ML, Taylor, JE, Culler, MD, Lombardi, G, Di Renzo, GF & Annunziato, L 2004, 'Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs', Neuroendocrinology, vol. 79, no. 3, pp. 142-148. https://doi.org/10.1159/000077272

Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML et al. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology. 2004;79(3):142-148. https://doi.org/10.1159/000077272

Matrone, C. ; Pivonello, R. ; Colao, A. ; Cappabianca, P. ; Cavallo, L. M. ; Del Basso De Caro, M. L. ; Taylor, J. E. ; Culler, M. D. ; Lombardi, G. ; Di Renzo, G. F. ; Annunziato, L. / Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. In: Neuroendocrinology. 2004 ; Vol. 79, No. 3. pp. 142-148.

@article{b6744bdc8061462181b9df1f507edf9f,

title = "Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs",

abstract = "The role of somatostatin (SS) receptor subtype 1 (SSTR1) in mediating the inhibitory effect of SS on growth hormone (GH) secreting pituitary tumors has been recently demonstrated. In the present study, we evaluated the effect of the selective SSTR1 agonist BIM-23745 on in vitro GH secretion in GH-secreting pituitary tumor cells, deriving from patients resistant or partially responsive to octreotide long-acting release (octreotide-LAR) or lanreotide therapy in vivo and expressing SSTR1 mRNA. In addition, the inhibiting effect of BIM-23745 on the GH secretion was compared with that of octreotide. Our data demonstrate that (1) SSTR1 receptor was present in 56.25% (9/16) of the GH-secreting adenomas examined; (2) in all GH-secreting pituitary tumors that expressed SSTR1, BIM-23745 significantly inhibited GH secretion in vitro, and (3) when SSTR 1 subtype was present in tumors from patients resistant to octreotide-LAR or lanreotide therapy, BIM-23745 was able to inhibit the in vitro GH secretion. In conclusion, the results of the current study suggest that SS analogs selective for the SSTR1 may represent a further useful approach for the treatment of acromegaly in patients resistant or partially responsive to octreotide-LAR or lanreotide treatment in vivo.",

keywords = "Acromegaly, Clinical neuroendocrinology, Growth hormone, Insulin-like growth factors, Somatostatin, Somatostatin analogs, Somatostatin receptors",

author = "C. Matrone and R. Pivonello and A. Colao and P. Cappabianca and Cavallo, {L. M.} and {Del Basso De Caro}, {M. L.} and Taylor, {J. E.} and Culler, {M. D.} and G. Lombardi and {Di Renzo}, {G. F.} and L. Annunziato",

year = "2004",

doi = "10.1159/000077272",

language = "English",

volume = "79",

pages = "142--148",

journal = "Neuroendocrinology",

issn = "0028-3835",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs

AU - Matrone, C.

AU - Pivonello, R.

AU - Colao, A.

AU - Cappabianca, P.

AU - Cavallo, L. M.

AU - Del Basso De Caro, M. L.

AU - Taylor, J. E.

AU - Culler, M. D.

AU - Lombardi, G.

AU - Di Renzo, G. F.

AU - Annunziato, L.

PY - 2004

Y1 - 2004

N2 - The role of somatostatin (SS) receptor subtype 1 (SSTR1) in mediating the inhibitory effect of SS on growth hormone (GH) secreting pituitary tumors has been recently demonstrated. In the present study, we evaluated the effect of the selective SSTR1 agonist BIM-23745 on in vitro GH secretion in GH-secreting pituitary tumor cells, deriving from patients resistant or partially responsive to octreotide long-acting release (octreotide-LAR) or lanreotide therapy in vivo and expressing SSTR1 mRNA. In addition, the inhibiting effect of BIM-23745 on the GH secretion was compared with that of octreotide. Our data demonstrate that (1) SSTR1 receptor was present in 56.25% (9/16) of the GH-secreting adenomas examined; (2) in all GH-secreting pituitary tumors that expressed SSTR1, BIM-23745 significantly inhibited GH secretion in vitro, and (3) when SSTR 1 subtype was present in tumors from patients resistant to octreotide-LAR or lanreotide therapy, BIM-23745 was able to inhibit the in vitro GH secretion. In conclusion, the results of the current study suggest that SS analogs selective for the SSTR1 may represent a further useful approach for the treatment of acromegaly in patients resistant or partially responsive to octreotide-LAR or lanreotide treatment in vivo.

AB - The role of somatostatin (SS) receptor subtype 1 (SSTR1) in mediating the inhibitory effect of SS on growth hormone (GH) secreting pituitary tumors has been recently demonstrated. In the present study, we evaluated the effect of the selective SSTR1 agonist BIM-23745 on in vitro GH secretion in GH-secreting pituitary tumor cells, deriving from patients resistant or partially responsive to octreotide long-acting release (octreotide-LAR) or lanreotide therapy in vivo and expressing SSTR1 mRNA. In addition, the inhibiting effect of BIM-23745 on the GH secretion was compared with that of octreotide. Our data demonstrate that (1) SSTR1 receptor was present in 56.25% (9/16) of the GH-secreting adenomas examined; (2) in all GH-secreting pituitary tumors that expressed SSTR1, BIM-23745 significantly inhibited GH secretion in vitro, and (3) when SSTR 1 subtype was present in tumors from patients resistant to octreotide-LAR or lanreotide therapy, BIM-23745 was able to inhibit the in vitro GH secretion. In conclusion, the results of the current study suggest that SS analogs selective for the SSTR1 may represent a further useful approach for the treatment of acromegaly in patients resistant or partially responsive to octreotide-LAR or lanreotide treatment in vivo.

KW - Acromegaly

KW - Clinical neuroendocrinology

KW - Growth hormone

KW - Insulin-like growth factors

KW - Somatostatin

KW - Somatostatin analogs

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=2342468214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342468214&partnerID=8YFLogxK

U2 - 10.1159/000077272

DO - 10.1159/000077272

M3 - Article

C2 - 15103227

AN - SCOPUS:2342468214

VL - 79

SP - 142

EP - 148

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 3

ER -